Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

70.63 +0.50 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable. ↗
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
News headline image
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief ↗
Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE... 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. ↗
Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts ↗
 
Via Benzinga
News headline image
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews ↗
 
Via Benzinga
News headline image
Analyst Expectations For Halozyme Therapeutics's Future ↗
 
Via Benzinga
News headline image
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting ↗
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options. 
Via Benzinga
News headline image
Peering Into Halozyme Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Investors should take notice of HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—it offers a great deal for the fundamentals it presents. ↗
HALOZYME THERAPEUTICS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:HALO showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive. ↗
Uncover the potential of HALOZYME THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:HALO is excelling in growth aspects, maintaining a healthy financial position, and still offers an... 
Via Chartmill
News headline image
Is HALOZYME THERAPEUTICS INC (NASDAQ:HALO) a Minervini-style stock? ↗
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:HALO). 
Via Chartmill
News headline image
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase. ↗
Based on a technical and fundamental analysis of NASDAQ:HALO we can say: HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Looking for growth without the hefty price tag? Consider HALOZYME THERAPEUTICS INC (NASDAQ:HALO). ↗
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
HALOZYME THERAPEUTICS INC has a stellar value proposition. NASDAQ:HALO not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Technical Analysis observations. ↗
Exploring HALOZYME THERAPEUTICS INC's Technical Signals and Breakout Potential: A technical analysis of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows it may be setting up for a breakout. 
Via Chartmill
News headline image
NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗
Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
Earnings Scheduled For February 18, 2025 ↗
 
Via Benzinga
News headline image
NASDAQ:HALO is not too expensive for the growth it is showing. ↗
HALOZYME THERAPEUTICS INC could be undervalued. NASDAQ:HALO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
News headline image
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals. ↗
Discover HALOZYME THERAPEUTICS INC, an undervalued stock. NASDAQ:HALO showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why. ↗
A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗
Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
News headline image
In the world of growth stocks, NASDAQ:HALO shines as a value proposition. ↗
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
News headline image
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
BeiGene Stock Meets 80-Plus RS Rating Benchmark ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
News headline image
BridgeBio Pharma Stock Earns 87 RS Rating ↗
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
News headline image
SpringWorks Therapeutics Stock Gets A RS Rating Lift ↗
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76. 
Via Investor's Business Daily
News headline image
Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗
Don't overlook HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.